Transcript
•
Dengue & Chikungunya Viral infections
Arbo Viral InfectionsRNA viruses
Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director
Academics, Industry: Research, Diagnosis, Public Health, Academics
Dengue• Of great antiquity, clinically known in China• Swahili “ka dinga pepo”• Along with slaves ; Africa Caribbean• In Cuba (Spanish) Dinga is Dengue (fastidious)• 4 closely related RNA viruses
– DEN 1, DEN 2, DEN 3, DEN 4– Share same geographical & ecological niche– Ss RNA, flavi virus
Dengue Virus
Mosquito Transmission: Aedes aegypti and Aedes albopictus
Transmission: Aedes mosquito• Aedes aegypti
– Urban mosquito– Needs standing water for larvae– Prefers cool, dark areas for resting– Feeds through the day, most active at dawn/dusk– Eggs do not survive winter in temperate climates
• Aedes albopictus: Asian Tiger Mosquito– Urban, periurban, rural habitats– Feeds through the day, most active dawn/afternoon– Eggs survive winter in temperate climates– Invasive- spreading in Europe and Americas
www.cdc.gov
•
•
•
•
Course of Dengue illness
•
•
•
•
Lumsden WH. Trans Roy Soc Trop Med Hyg 1955;49:33-57
Chikungunya Virus (CHIKV): Alphavirus
• “That which bends up” in Swahili• Togaviridae family • Single strand RNA virus, mosquito-transmitted
www.cdc.gov/ncidod/dvbid/arbor/alphavir.htm
20
What is Chikungunya?• Chikungunya is a virus that is transmitted from human
to human mainly by infected Aedes albopictus and Aedes aegypti mosquitoes acting as the disease-carrying vector
• Chikungunya causes sudden onset of high fever, severe
joint pain, muscle pain and headache– 3 main presentations
• Acute: – sudden onset,– Severe, incapacitating polyarthralgia– Maculopapular rash on trunk & extremities
• Subacute:– Relapse of symptoms 2 to 3 months following initial infection– Exacerbated pain in previously affected joints
• Chronic:– Persistence of arthralgia & fatigue for > 3 months– Prevalence in 12 to 50%
21
Symptoms
• Symptoms include:
Sudden onset of high feverHeadacheBack painMyalgiaArthralgia
• The symptoms will appear on average 4 to 7 days (but can range from 1 to 12 days) after being bitten by an infected Aedes mosquito
Mosquito Transmission: Aedes aegypti and Aedes albopictus
Transmission: Aedes mosquito• Aedes aegypti
– Urban mosquito– Needs standing water for larvae– Prefers cool, dark areas for resting– Feeds through the day, most active at dawn/dusk– Eggs do not survive winter in temperate climates
• Aedes albopictus: Asian Tiger Mosquito– Urban, periurban, rural habitats– Feeds through the day, most active dawn/afternoon– Eggs survive winter in temperate climates– Invasive- spreading in Europe and Americas
www.cdc.gov
24
Epidemiology Chikungunya risk zones
Outbreaks of Chikungunya virus are usually found in:– Africa– Southeast Asia– Indian subcontinent and islands in the Indian Ocean
CHIKV: re-emerging disease• Initial descriptions in 1950s• 2000 Epidemic in Kinshasa, DRC,
1st in 39 years• 2001-2003 epidemic in Indonesia,
1st in 20 years• 2004 Coastal Kenya
– E226V mutation more efficiently transmitted by Aedes albopictus
– 2005 Spread to Comoros Islands • 2005-2007 Epidemic in Réunion:
35% attack rate– 266,000 cases– 0.1% mortality
• 2006 Maldives & India• 2008 Singapore• 2012 Rural Cambodia
– 44.7% prevalence– 5.3% asymptomatic
• 2012 Bhutan– 1st cases reported– Index case recent travel from
India– East/Central/South African
genotype• 2012 Papua New Guinea
– 1st cases reported
MMWR 2012; 61: 737-40www.cdc.gov/eid 2013 vol 19
Treatment and Prevention• Acute Illness
– Supportive care– NSAIDS– Case reports of short steroid courses for severe early
disease• Persistent arthralgias: no good data for treatment
– Chloroquine, hydroxychloroquine • No sig difference in efficacy for acute arthralgias
between chloroquine and meloxicam in 509 indiv in India
– Sulfasalazine, methotrexate, ribavirin, interferon-alpha• Mosquito avoidance• Vaccines in research, not licensed• Monoclonal antibodies as prophylaxis effective in mouse
models
Incubation Period
42
What should I do if I suspect my patient has Chikungunya?
Chikungunya is a reportable disease. ECDC proposes the following reporting levels:
Case categories
• Possible case: a patient meeting clinical criteria
• Probable case: a patient meeting both the clinical and epidemiological criteria
• Confirmed case: a patient meeting the laboratory criteria, irrespective of the clinical presentation
43
Algorithm for ascertainment of suspected Chikungunya case
Source: ECDC Mission Report: Chikungunya in Italy, Joint ECDC/WHO visit for a European risk assessment 17 – 21 September 2007
Protection
• Personal protection: DEET, Picaridin• Household prevention: Screen, Bed nets• Neighbourhood & community prevention• Vector Control
– Same as for Dengue vector control
top related